Visual Abstract

Increasing physical activity (PA) in minority populations with type 2 diabetes (T2D) is likely to have important cardiometabolic benefits. The aim of this study is to determine feasibility and acceptability of using wearable accelerometers to assess PA, as part of creating a unique, real-world dataset on health determinants, in Hispanic/Latino adults with or at risk for T2D. PA was measured using an ActiGraph wGT3X-BT worn on the right hip 24 hours/day for 7 consecutive days. Insulin resistance (HOMA IR) and Metabolic Syndrome Score (MetS z) were calculated in 157 Hispanic/Latino participants [107 women, (mean ±SD) age 56.7 ± 11.0 years, (median [IQR]) HbA1c 7.6 [6.5, 9.4] %]. For those diagnosed with T2D, n=133, duration of diabetes was 13.2±9.0 years. There were significant correlations between Weekday steps and age (-0.31), waist circumference (WC) (-0.30), and BMI (-0.22) (p<0.01). When stratified into 3 groups by Weekday steps (A <4,400, B 4,400 - 7,999, C ≥8,000), group A was significantly different from group C for age (63.8±8.4 vs. 53.3±9.9 years) and WC (111.1±12.9 vs. 96.6±10.7 cm).

In conclusion, PA during Weekdays is higher than Weekends for Hispanic/Latino adults with or at risk for T2D. Weekday steps were also associated with a smaller WC and thus lower cardiometabolic risk. In this population, women were significantly more obese and insulin resistant than men.

Disclosure

W. C. Bevier: Research Support; Self; Abbott Diabetes, Eli Lilly and Company. A. J. Larez: Research Support; Self; Abbott, Eli Lilly and Company. C. Conneely: Research Support; Self; Abbott, Eli Lilly and Company. N. M. Glantz: Research Support; Self; Abbott, Eli Lilly and Company. K. N. Castorino: Consultant; Self; Dexcom, Inc., Research Support; Self; Abbott Diabetes, Abbott Laboratories, Dexcom, Inc., Drawbridge Health, Inc., Lilly Diabetes, Medtronic, Novo Nordisk Inc. D. Kerr: Advisory Panel; Self; Novo Nordisk, Sanofi-Aventis, Research Support; Self; Abbott Diabetes, Elsevier, Lilly Diabetes, Stock/Shareholder; Self; Glooko, Inc.

Funding

Eli Lilly and Company

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.